Clinical trial NCT05220306: AIDI - Research & Development of a Multisensor-Based Machine Learning Technology for Real-Time Automated Detection of COVID-19 Decompensation
Official title: AIDI - Research & Development of a Multisensor-Based Machine Learning Technology for Real-Time Automated Detection of COVID-19 Decompensation
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Sars-CoV-2 Infection
Lead sponsor: AIDAR Health, Inc.
Sponsor class: INDUSTRY
Collaborators: name: Avania
First posted: 2022-02-02
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Intervention model description: Phase I/Derivation Cohort (100 patients):

This phase will use the MouthLab to capture vital signs. This data will help create Aidar's algorithm-based decompensation index (AIDI) that utilizes changes in vital signs to identify individuals who test positive for SARS-CoV-2 or with COVID-19 infection and are at risk of developing clinical decompensation.

Phase II/Validation Cohort (400 patients):

This phase will use the MouthLab to capture vital signs and use Aidar's algorithm-based decompensation index (AIDI) to identify individuals at risk of clinical decompensation.
Primary purpose: DIAGNOSTIC

Brief summary: The AIDI study has to phases. It's purpose is to capture vital signs using a non-invasive, hand-held, home monitoring device (MouthLab Device) from individuals with COVID-19 or who test positive for SARS-CoV-2 (Phase I) and use an algorithm-based approach to identify individuals at risk of clinical decompensation (Phase II). Up to 500 unvaccinated and partially vaccinated subjects will be included (up to 100 in Phase I and up to 400 in Phase II).


Eligibility criteria: Inclusion Criteria:

* Male or female 18 years of age or older
* Unvaccinated individuals, or individuals who have received only 1 dose of an mRNA vaccine
* Individuals who have received a positive SARS-CoV-2 result within 24-48 hours (lab-based PCR or antigen test)
* Willing and able to provide informed consent
* Ability to read, write, and comprehend English
* Have no functional limitation that would impede the use of the MouthLab device
* Willing to provide access to health information via electronic health records (EHR)

Exclusion Criteria:

* Currently receiving hospice care
* Have a left ventricular assist device
* Left-sided hemiplegia or any other motor deficits that may restrict the use of the device.
* individuals with cognitive deficits that impede their ability to comprehend and give informed consent.
* Individuals who are enrolled in any other investigational research studies of SARS-CoV2 or COVID-19
* Individuals who are treated with monoclonal antibody therapy prior to diagnosis
* Individuals who are admitted to a hospital or acute care facility at the time of diagnosis
* Individuals with pacemakers or implanted cardio-defibrillators (ICDs)
* History of hemoptysis, pneumothorax, thoracic or abdominal aneurysm, pulmonary embolism, or stroke
* History of unstable cardiovascular status, including recent myocardial infarction (MI within 30 days), unstable angina, or uncontrolled hypertension Color blindness
* Chest, abdominal or eye surgery within the preceding 14 days
* Any condition that in the judgment of the investigators would interfere with the subject's ability to provide informed consent, comply with study instructions, place the subject at increased risk, or which might confound interpretation of study results.

Primary outcomes:
measure: Collect trends in physiological vital signs and symptom burden to identify individuals who are at risk of clinical decompensation
timeFrame: Daily for 60 days
measure: AIDI evaluation
timeFrame: Daily for 60 days
Secondary outcomes:
measure: Usability of MouthLab device
timeFrame: At 60 days
measure: Evaluate any short-term changes in vital signs among patients with underlying comorbid conditions
timeFrame: Day 0 to Day 60
Other outcomes:
Locations:
city: San Jose
country: United States
facility: Maxis Llc
state: California
Study officials:
affiliation: Avania
name: Sujith Shetty, MD
role: PRINCIPAL_INVESTIGATOR
References: